This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Molecular Cancer Open Access 15 February 2010
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kolb JP, Kern C, Quiney C, Roman V, Billard C . Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Hematol Disord 2003; 3: 261–286.
Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399–404.
Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379–3389.
Quiney C, Billard C, Faussat AM, Salanoubat C, Ensaf A, Naït-Si Y et al. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 2006; 20: 491–497.
Quiney C, Billard C, Salanoubat C, Fourneron JD, Kolb JP . Hyperforin, a new lead compound against the progression of cancer and leukemia? Leukemia 2006; 20: 1519–1525.
Willis SN, Adams JM . Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17: 617–625.
Smit L, Hallaert DYH, Spijker R, de Goeij B, Jaspers A, Kater AP et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlate with survival capacity. Blood 2007; 109: 1660–1668.
Billard C, Kern C, Tang R, Ajchenbaum-Cymbalista F, Kolb JP . Flavopiridol downregulates the expression of both the inducible NO synthase and p27kip1 in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 2003; 17: 2345–2443.
Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65: 6282–6293.
Pérez-Galan P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D . The proteasome inhibitor bortezomid induces apoptosis in mantle-cell lymphome through generation of ROS and Noxa induction activation independent of p53 status. Blood 2006; 107: 257–264.
Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM . Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007; 21: 1773–1782.
Pérez-Galan P, Roué G, Lopez-Guerra M, Nguyen M, Villamor N, Montserrat E et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, e-pub ahead of print 3 July 2008; doi: 10.1038/leu.2008.175.
This work was supported by INSERM, Université Pierre et Marie Curie-Paris 6 and by a grant from Canceropole Ile-de-France. We are indebted to Dr JD Fourneron for his gift of hyperforin and to Professor JP Marie and colleagues for providing the blood samples of patients.
About this article
Cite this article
Zaher, M., Akrout, I., Mirshahi, M. et al. Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol. Leukemia 23, 594–596 (2009). https://doi.org/10.1038/leu.2008.239
Molecular Cancer (2010)